The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015

London, United Kingdom (PressExposure) December 05, 2009 -- The global CNS therapeutics market was valued at $99 billion in 2008 and will be driven by the increasing ageing population and the steady increase in incidence rates of CNS complications. This market is expected to grow to $121 billion with a CAGR of 2.8% by year 2015. GBI Research examined the CNS markets in US, EU5 (includes UK, France, Germany, Italy and Spain) and Japan. Of all the covered countries, the market size in US was the largest as compared to other regions. The market is also growing the fastest in US as compared to other regions. This is explained primarily by both the price differentials that are observed in US at a higher rate compared to other regions as well as the higher volume of diseased and pharmacotherapy treated population.

For further details on this report, please click or copy the below link to your browser:

Globally, the US remains the largest sector in terms of revenues. The US CNS therapeutics market in 2008 represented 52 % share over the total CNS therapeutics market. Countries like China and India have been identified as potential emerging markets for major pharmaceutical companies to invest in. A major factor posing a threat to this market is the expiration of patents for many block buster drugs in the next three years. The entry of generic substitutes at substantially lower prices could be very debilitating for major manufacturers. Markets like Japan and other south Asian countries have shown increasing acceptance of generics under their reimbursement protocols. European countries face high risk from parallel importing coupled with effective bans on the reimbursements for certain CNS diseases.

For further details on this report, please click or copy the below link to your browser:

GBI Research analyzed environmental and industry trends to assess the market evolution. Most trends observed in the pharmaceutical industry support the forecasting models, drivers and barriers outlined above. The top pharmaceuticals companies are seeing rapid increases in research and development costs accompanied by declining drug sales. DTC campaigns as promotional tactics are being used increasingly across the pharmaceutical industry. Reimbursements for almost all therapeutic areas, including CNS, are under severe pressure. Taken together the industry and environmental trends suggest that CNS therapeutic area is likely to see increasing market value in the next few years.

GBI, the leading business intelligence provider has released its latest research, “The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis” provides key data, information and analysis on the global CNS therapeutics market. The report provides market landscape, competitive landscape and market trends information on seven disease categories which include; Alzheimer’s disease, Parkinson’s disease, Schizophrenia and Bi-polar disorder, Major Depressive Disorder, Anxiety and Panic disorder, Attention Deficit Hyperactivity Disorder and Insomnia.

The report also provides annualized market revenues data from 2000 to 2008, forecast until 2015 for all the mentioned disease sectors. The report covers seven geographies which include; the US, the UK, Germany, France, Spain and Italy and Japan. This report provides comprehensive information on the key trends effecting these categories, and key analytical content on the market dynamics. The report also reviews the competitive landscape in terms of mergers and acquisitions, pipeline products and technology offerings. In-depth analysis of the report is based on propriety databases, primary and secondary research and in house analysis by GBI Research team of experts.

For further details on this report, please click or copy the below link to your browser:

Or Visit our report store:

About Global Business Intelligence

Global Business Intelligence is a global market intelligence services company providing information research and analysis products and services.

Press Release Source:

Press Release Submitted On: December 05, 2009 at 12:30 am
This article has been viewed 24513 time(s).